Coenzyme Q10 and Meclofenoxate in Hepatic Encephalopathy

• Status: Unknown status
• Trial end date: 2020-02-01
• Target enrollment: 0
• Participant gender: All

Summary

Hepatic encephalopathy is a syndrome occurs in patients with liver cirrhosis and is defined as neuropsychiatric abnormalities in patients with liver impairment, characterized by personality changes, intellectual impairment, and an impaired level of consciousness.

Coenzyme Q10 (CoQ10) is a necessary cofactor of the mitochondrial metabolism. It provides a High antioxidant and protective effects on age-related morbidities such as hypertension, heart failure and neurodegenerative diseases and hepatoprotective effects in drug related hepatic impairment.

Meclofenoxate is a cholinergic nootropic drug used clinically to improve memory, mental function and general cognition.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Zagazig University
• Treatments: Coenzyme Q10; Meclofenoxate; Ubiquinone

Criteria

Inclusion Criteria:

• All the patients diagnosed as having liver cirrhosis Exclusion Criteria

• recent alcohol intake;

• Infection, recent antibiotic use or gastrointestinal bleeding;

• use of drugs affecting psychometric Performances like benzodiazepines, antiepileptics, psychotropic drugs

• History of shunt surgery or transjugular intrahepatic portosystemic shunt for portal hypertension;

• Electrolyte abnormalities

• Renal impairment or hepatorenal syndrome

• hepatocellular carcinoma;

• Severe medical co-morbidities that affect quality-of-life measurement as heart failure pulmonary or neurological insults.